INS and early-onset autosomal dominant Alzheimer disease: One major example is represented by the IN drug delivery of insulin, investigated in the SNIFF clinical trials as a possible treatment for cognitive defects in patients affected by Alzheimer’s disease (clinicaltrials.gov: NCT03857321, NCT00438568, NCT01767909).